Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer Jan Nyrop JakobsenJens Benn Sørensen Mini Review 01 December 2011 Pages: 289 - 299
Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin Shoaib AfzalSøren Astrup JensenHenrik Enghusen Poulsen Original Article 28 June 2011 Pages: 301 - 307
Imatinib mesylate in thymic epithelial malignancies Giovannella PalmieriMirella MarinoVincenzo Damiano Original Article 28 June 2011 Pages: 309 - 315
Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2 Cheng Zhen LiangJia Kai ZhangHui Min Tao Original Article 30 June 2011 Pages: 317 - 331
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors B. SchultheisG. KummerD. Strumberg Original Article 08 July 2011 Pages: 333 - 339
Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies R. ThertulienG. M. ManikhasA. P. Staddon Original Article Open access 08 July 2011 Pages: 341 - 350
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) Ioannis BoukovinasNikolaos AndroulakisVassilis Georgoulias Original Article 12 July 2011 Pages: 351 - 356
Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy Olivier MirNarjiss BerradaAxel Le Cesne Original Article 19 July 2011 Pages: 357 - 367
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer Francesco GrossiFilippo de MarinisEnzo Galligioni Original Article 21 July 2011 Pages: 369 - 375
Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance Yongsheng JiaWenjian ZhangJinning Lou Original Article 22 July 2011 Pages: 377 - 385
Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study Xiao-Jian LiuYe GuoXiao-Nan Hong Original Article 26 July 2011 Pages: 387 - 395
Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children Gisela KerstingStefan WillmannGeorg Hempel Original Article 26 July 2011 Pages: 397 - 405
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601) Wasaburo KoizumiNorisuke NakayamaChikatoshi Katada Original Article 28 July 2011 Pages: 407 - 413
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma Ana De Jesus-AcostaGeorge R. OliverLuis A. Diaz Jr. Original Article Open access 29 July 2011 Pages: 415 - 424
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis Hassan K. DakikDaniel J. MoskovicDavid R. Fogelman Original Article 18 August 2011 Pages: 425 - 430
Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors Giovanna SperanzaMartin E. GutierrezAlice Chen Original Article 31 July 2011 Pages: 431 - 438
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer Taroh SatohYasuhide YamadaNarikazu Boku Original Article 19 August 2011 Pages: 439 - 446
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation Ines PauleMichel TodPascal Girard Original Article 02 August 2011 Pages: 447 - 455
Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer Masashi AndoKan YonemoriYasuhiro Fujiwara Original Article 19 August 2011 Pages: 457 - 465
Nucleoside transporters are widely expressed in ovarian carcinoma effusions Annika J. BockHiep Phuc DongBen Davidson Original Article 06 August 2011 Pages: 467 - 475
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study N. XenidisL. ChelisS. Kakolyris Original Article 20 August 2011 Pages: 477 - 484
Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer Xiangdong MaJianfang ZhangDetang Wang Original Article 13 August 2011 Pages: 485 - 494
Probenecid is a chemosensitizer in cancer cell lines Denise Campos-ArroyoJuan Carlos MartÃnez-LazcanoJorge Melendez-Zajgla Original Article 23 August 2011 Pages: 495 - 504
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors J. PortnowP. FrankelT. W. Synold Original Article 18 August 2011 Pages: 505 - 514
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study Zhonghua WangJingsong LuXichun Hu Original Article 27 August 2011 Pages: 515 - 522
Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors Elaine T. LamSanjay GoelMiguel A. Villalona-Calero Original Article 27 August 2011 Pages: 523 - 531
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial P. SkarlosC. ChristodoulouG. Fountzilas Original Article 08 September 2011 Pages: 533 - 546
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies Julie BaumanClaire VerschraegenDennie Jones Original Article 08 September 2011 Pages: 547 - 554
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer Geoffrey I. ShapiroRichard FrankLionel D. Lewis Clinical Trial Report 06 November 2011 Pages: 555 - 562
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer Heather A. WakeleeChris H. TakimotoJordi Rodon Clinical Trial Report 06 November 2011 Pages: 563 - 571
Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane Seppo W. LangerAnnemette V. ThougaardPeter Buhl Jensen Short Communication 06 December 2011 Pages: 573 - 576